Related Experiment Videos
Preliminary phase I study of 4'-epi-adriamycin
Cancer Treatment Reports
|May 1, 1979
Summary
This phase I study found that 4'-epi-Adriamycin (4'-epi-ADM) showed similar toxicity to Adriamycin but with less severe side effects. Further clinical studies are recommended for this potential cancer therapeutic.
Area of Science:
- Oncology
- Pharmacology
- Clinical Trials
Background:
- Advanced solid tumors present significant treatment challenges.
- Adriamycin is a known chemotherapeutic agent with established toxicity profiles.
- Novel analogs like 4 -epi-ADM are explored to improve therapeutic efficacy and reduce side effects.
Purpose of the Study:
- To evaluate the safety and preliminary efficacy of 4 -epi-ADM in patients with advanced solid tumors.
- To characterize the acute toxicity pattern of 4 -epi-ADM.
- To compare the toxicity of 4 -epi-ADM with that of Adriamycin.
Main Methods:
- A phase I clinical trial was conducted.
- Twenty-two patients with various advanced solid tumors were enrolled.
- Toxicity, including vomiting, alopecia, and marrow suppression, was assessed.
Main Results:
- 4 -epi-ADM exhibited a toxicity pattern similar to Adriamycin.
- Incidence of vomiting, alopecia, and marrow suppression was less pronounced with 4 -epi-ADM.
- Prolongation of the systolic time interval was observed, but no clinical cardiotoxicity was noted.
- Objective tumor responses were seen in two patients (renal carcinoma and malignant melanoma).
Conclusions:
- 4 -epi-ADM demonstrates a potentially favorable toxicity profile compared to Adriamycin.
- The drug shows preliminary signs of efficacy in specific advanced solid tumors.
- Further clinical investigation of 4 -epi-ADM is warranted.